Drug Profile
Seasonal influenza virus vaccine inactivated split-trivalent - GlaxoSmithKline
Alternative Names: 2186877A; GSK 2186877A; New generation flu vaccine (inactivated split - trivalent) - GlaxoSmithKlineLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 28 May 2010 GlaxoSmithKline completes a phase III trial (NCT00753272) in Influenza virus infections in the EU, Canada, Mexico, Russia and Taiwan
- 13 Mar 2006 Phase-II clinical trials in Influenza virus infections in Europe (unspecified route)
- 22 Dec 2003 Phase-I clinical trials in Influenza virus infections in Europe (unspecified route)